Zobrazeno 1 - 10
of 16
pro vyhledávání: '"H Laterveer"'
Autor:
Ria H. Laterveer, Annelieke C. Kruithof, Cornelis Kluft, Matthijs Moerland, Pieter-Jan de Kam, Jacobus Burggraaf
Publikováno v:
Int. Journal of Clinical Pharmacology and Therapeutics. 59:89-98
Objective To explore the mode of action (MoA) by which sugammadex interferes with coagulation. Materials and methods The effect of sugammadex on various steps in the coagulation cascade including thrombin generation, factor Xa activity, and factor Xa
Autor:
Cornelis Kluft, Annelieke C. Kruithof, Geertruida H Laterveer, Jacobus Burggraaf, Matthijs Moerland, Pieter-Jan de Kam
Publikováno v:
International journal of clinical pharmacology and therapeutics. 58(7)
Objective To investigate in vitro the effect of sugammadex on activated partial thromboplastin time (APTT) and prothrombin time (PT) prolongations with various anticoagulants as well as the neutralizing effect of rocuronium and vecuronium on sugammad
Autor:
Michael Schuler, F. Weilbach, M. Lukasczik, M. Presl, J. Knörzer, Silke Neuderth, H. Laterveer
Publikováno v:
Die Rehabilitation. 55:312-318
Ziel der Studie: Die MBO ® Kompakt-Neurowoche wird nach arztlicher Zuweisung als 7-tagige berufsorientierte Reha-Masnahme im Anschluss an eine regulare neurologische Rehabilitation durchgefuhrt. Zugang, Durchfuhrung und Outcomes werden formativ eval
Publikováno v:
Die Rehabilitation. 55(5)
Autor:
Han Speijer, Ria H Laterveer-Vreeswijk, Jan F. C. Glatz, Wim Th. Hermens, Willem Nieuwenhuizen
Publikováno v:
Analytical Biochemistry. 326:257-261
Standard enzyme immunoassays (EIAs) require washing steps to remove excess enzyme–antibody complexes. Such washing is laborious, lengthens assay time, and increases assay scatter. Recently, so-called precipitate-enhanced immunoassays (PEIAs) were i
Die MBO® Kompakt-Neurowoche: Wer nimmt daran teil und wie geht es den Rehabilitanden nach 6 Monaten?
Publikováno v:
Zeitschrift für Palliativmedizin. 15
Publikováno v:
Thrombosis and Haemostasis. 81:54-59
SummaryFibrin formation is a multistep process initiated by thrombin. At first thrombin converts fibrinogen to fibrin molecules which in vivo form soluble complexes with fibrinogen. Soluble fibrin is considered to be an early biochemical marker for i
Publikováno v:
Blood coagulationfibrinolysis : an international journal in haemostasis and thrombosis. 24(3)
The exclusion of deep venous thrombosis (DVT) in the elderly is hampered by low specificity in clinical decision of D-dimer assays in older patients. To reduce false-positive results, we evaluated specific fibrin(ogen) degradation product assays for
Autor:
Lonneke M. L. de Lau, Elim Y. L. Cheung, Diederik W.J. Dippel, Ria H. Laterveer, Piet Meijer, Moniek P.M. de Maat, Frank W.G. Leebeek, Cornelis Kluft
Publikováno v:
British Journal of Haematology, 143(5), 734-737. Wiley-Blackwell Publishing Ltd
Ischemic stroke is associated with leucocyte activation. Activated leucocytes release elastase, an enzyme that can degrade fibrinogen. Fibrinogen elastase degradation products (FgEDP) may serve as a specific marker of elastase proteolytic activity. I
Autor:
M. Cornelissen, Jan N. M. Commandeur, L. van Bree, B Lamberts, M van Roon, J. A. de Vries, H Laterveer
Publikováno v:
Journal of Biochemical Toxicology. 5:57-63
The effects of pretreatment with symmetrically dihalogenated biphenyls (DXBs, X-F, Cl(C), Br(B) and I) on rat liver drug metabolism enzymes were investigated. 4,4′-DFB, -DCB, and -DBB as well as 2,2′-DFB appeared to be inducers of microsomal cyto